Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

11/03/2015 Sustainability: the Barcelona Synchrotron Park focuses on birds and bats… 05/03/2015 Wastewater that produces green energy 26/02/2015 ALBA, CSIC and Alibava develop an X-Ray detector 20/02/2015 The pressure that makes conductivity higher: new record in the ICN2 11/02/2015 Presentation of the Big Data CoE Barcelona initiative 06/02/2015 Come investigate at the ALBA synchrotron: 2015 new call for proposals
34 35 36 37 38 39 40 41 42 43 44